Medicus Pharma Q3 net loss $16M, pipeline advances with SkinJect and Teverelix

Medicus Pharma Ltd.

Net loss $16.0M in Q3 2025 vs $2.3M in Q3 2024; R&D $1.7M, G&A $5.0M.
Cash $8.7M at Sep 30, 2025, up from $5.3M; raised $10.4M from financings and warrant exercises.
Phase 2 SKNJCT-003 >75% enrolled; FDA Type C meeting supports 505(b)(2) pathway for D-MNA (BCC).
Completed Antev acquisition (Teverelix, GnRH antagonist) in August 2025; UK approvals for SKNJCT-003 expansion.
Strategic collaboration with Gorlin Syndrome Alliance for expanded access to SkinJect under FDA IND.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.